Vacchelli Erika, Pol Jonathan, Bloy Norma, Eggermont Alexander, Cremer Isabelle, Fridman Wolf Hervé, Galon Jérôme, Marabelle Aurélien, Kohrt Holbrook, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
Gustave Roussy Cancer Campus ; Villejuif, France ; INSERM; U1138 ; Paris, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer; Centre de Recherche des Cordeliers ; Paris, France.
Gustave Roussy Cancer Campus ; Villejuif, France.
Oncoimmunology. 2015 Feb 3;4(1):e985940. doi: 10.4161/2162402X.2014.985940. eCollection 2015 Jan.
An expanding panel of monoclonal antibodies (mAbs) that specifically target malignant cells or intercept trophic factors delivered by the tumor stroma is now available for cancer therapy. These mAbs can exert direct antiproliferative/cytotoxic effects as they inhibit pro-survival signal transduction cascades or activate lethal receptors at the plasma membrane of cancer cells, they can opsonize neoplastic cells to initiate a tumor-targeting immune response, or they can be harnessed to specifically deliver toxins or radionuclides to transformed cells. As an indication of the success of this immunotherapeutic paradigm, international regulatory agencies approve new tumor-targeting mAbs for use in cancer patients every year. Moreover, the list of indications for previously licensed molecules is frequently expanded to other neoplastic disorders as the results of large, randomized clinical trials become available. Here, we discuss recent advances in the preclinical and clinical development of tumor-targeting mAbs for oncological indications.
现在有一组不断扩大的单克隆抗体（mAb）可用于癌症治疗，这些抗体特异性靶向恶性细胞或拦截肿瘤基质传递的营养因子。这些单克隆抗体可发挥直接的抗增殖/细胞毒性作用，因为它们抑制促生存信号转导级联反应或激活癌细胞质膜上的致死受体，它们可调理肿瘤细胞以引发肿瘤靶向免疫反应，或者可用于将毒素或放射性核素特异性递送至转化细胞。作为这种免疫治疗模式成功的一个标志，国际监管机构每年都会批准新的肿瘤靶向单克隆抗体用于癌症患者。此外，随着大型随机临床试验结果的公布，先前已获许可分子的适应证列表经常会扩大到其他肿瘤性疾病。在此，我们讨论用于肿瘤适应证的肿瘤靶向单克隆抗体在临床前和临床开发方面的最新进展。
